Analysts think SNDX stock price could increase by 174%
Aug 09, 2025, 11:25 AM
36.84%
What does SNDX do
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
15 analysts think SNDX stock price will increase by 174.24%. The current median analyst target is $34.17 compared to a current stock price of $12.46. The lowest analysts target is $17.17 and the highest analyst target is $53.55.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
